Overview
I am a physician-scientist and stem cell biologist focused on understanding the fundamental mechanisms involved in lung injury and repair. I am particularly interested in determining the critical components of the alveolar epithelial stem cell niche and the cellular crosstalk signals that dictate cell identity and behavior during steady state maintenance and repair after injury and infection. I believe this work is fundamental to better understanding the biology of the human lung and the pathogenesis of idiopathic pulmonary fibrosis (IPF), a disease that is characterized by relentless scar accumulation in the lung with only minimally effective therapy short of lung transplant.
Through my work, I have developed several areas of expertise which include the following: 1) Development and use of mouse models to genetically manipulate and lineage trace specific cell populations; 2) Isolation and characterization of murine lung cell subpopulations by flow cytometry; 3) Development and use of an ex vivo 3-dimensional organoid assay to study the self-renewal and differentiation of murine alveolar epithelial stem cells and their niche components; 4) Isolation and 3-dimensional culture of alveolar epithelial cells from fresh human lung; 5) Development and analysis of models of experimental lung fibrosis.
Current Appointments & Affiliations
Recent Publications
Hyaluronan Directs Alveolar Type II Cell Response to Acute Ozone Exposure in Mice.
Journal Article Am J Respir Cell Mol Biol · July 2025 Becoming more frequent because of climate change, ozone (O3) exposures can cause lung injury. Alveolar type 2 (AT2) cells and hyaluronan (HA), a matrix component, are critical to repairing lung injury and restoring homeostasis. Here, we define the impact o ... Full text Link to item CitePassive immunotherapy for adults hospitalized with COVID-19: An individual participant data meta-analysis of six randomized controlled trials.
Journal Article PLoS Med · July 2025 BACKGROUND: Anti-SARS-CoV-2 monoclonal antibodies (mAb) reduce the risk of hospitalization in outpatients with mild-to-moderate COVID-19. However, the efficacy of treatment with mAbs and other passive immunotherapies in patients hospitalized with severe CO ... Full text Link to item CiteRetraction Notice to: Nuclear respiratory factor-1 negatively regulates TGF-β1 and attenuates pulmonary fibrosis.
Journal Article iScience · June 20, 2025 [This retracts the article DOI: 10.1016/j.isci.2021.103535.]. ... Full text Link to item CiteRecent Grants
1/2 PREcision VENTilation to attenuate Ventilation-Induced Lung Injury (PREVENT VILI)
Clinical TrialPrincipal Investigator · Awarded by Beth Israel Deaconess Medical Center · 2024 - 2031ARDS, Pneumonia, and Sepsis Phenotyping Consortium Clinical Centers (APS)_Fixed Budget
ResearchPrincipal Investigator · Awarded by Intermountain Healthcare · 2024 - 2029Phase 2 Clinical Platform Trial Investigating Multiple Therapeutic Options for the Treatment of Hospitalized Patients with Acute Respiratory Distress Syndrome (ARDS)
Clinical TrialPrincipal Investigator · Awarded by PPD Investigator Services, LLC · 2025 - 2027View All Grants